0001209191-22-039532.txt : 20220627
0001209191-22-039532.hdr.sgml : 20220627
20220627190447
ACCESSION NUMBER: 0001209191-22-039532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220623
FILED AS OF DATE: 20220627
DATE AS OF CHANGE: 20220627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOUMEAU ERIC J
CENTRAL INDEX KEY: 0001239648
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 221046091
MAIL ADDRESS:
STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS
STREET 2: 4435 EASTGATE MALL STE.400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-23
0
0001370053
ANAPTYSBIO, INC
ANAB
0001239648
LOUMEAU ERIC J
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
CA
92121
0
1
0
0
COO, General Counsel
Stock Option (right to buy)
29.70
2022-06-23
4
A
0
10000
0.00
A
2022-06-23
2031-02-09
Common Stock
10000
10000
D
On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award.
In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 298,000 shares of common stock, which options vest according to their terms, and (ii) 523 shares of common stock held directly.
/s/ Eric Loumeau
2022-06-27